Ionis Pharmaceuticals IONS Increase (Decrease) in Contract with Customer, Asset
Increase (Decrease) in Contract with Customer, Asset at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset?
- Ionis Pharmaceuticals (IONS) reported increase (decrease) in contract with customer, asset of $7.63M in Q1 2026.
- How has Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset changed year-over-year?
- Ionis Pharmaceuticals's increase (decrease) in contract with customer, asset increased by 114.5% year-over-year, from -$52.48M to $7.63M.
- What does increase (decrease) in contract with customer, asset mean?
- The change in value of work performed for customers that has not yet been billed.
- How do you interpret increase (decrease) in contract with customer, asset?
- An increase suggests growing unbilled revenue from milestones, while a decrease indicates the conversion of these assets into billed receivables or cash.
- How does increase (decrease) in contract with customer, asset compare across companies?
- Common in companies with milestone-heavy revenue models; peers show similar fluctuations based on contract phases.